N‐(5‐((diphenylmethylene)amino)‐2‐methoxypyridin‐3‐yl)methanesulfonamide | 1253577-72-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N‐(5‐((diphenylmethylene)amino)‐2‐methoxypyridin‐3‐yl)methanesulfonamide
• 英文别名: N-(5-(diphenylmethyleneamino)-2-methoxypyridin-3-yl)methanesulfonamide；N-[5-(benzhydrylideneamino)-2-methoxypyridin-3-yl]methanesulfonamide
• CAS: 1253577-72-8
• 化学式: C₂₀H₁₉N₃O₃S
• 分子量: 381.455
• InChiKey: QEWLHDRGNODNHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  89
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N‐(5‐((diphenylmethylene)amino)‐2‐methoxypyridin‐3‐yl)methanesulfonamide 在 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 N‐(5‐amino‐2‐methoxypyridin‐3‐yl)methanesulfonamide
  参考文献：
  名称：

  Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold

  摘要：

  Phosphoinositide 3-kinase (PI3K) is an important target in oncology due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors. A series of 4-amino-6-methyl-1,3,5-triazine sulfonamides were synthesized and evaluated as inhibitors of PI3K. The synthesis, in vitro biological activities, pharmacokinetic and in vivo pharmacodynamic profiling of these compounds are described. The most promising compound from this investigation (compound 3j) was found to be a pan class I PI3K inhibitor with a moderate (>10-fold) selectivity over the mammalian target of rapamycin (mTOR) in the enzyme assay. In a U87 MG cellular assay measuring phosphorylation of Akt, compound 3j displayed low double digit nanomolar IC50 and exhibited good oral bioavailability in rats (F-oral = 63%). Compound 3j also showed a dose dependent reduction in the phosphorylation of Akt in a U87 tumor pharmacodynamic model with a plasma EC50 = 193 nM (91 ng/mL). (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.078
• 作为产物：
  描述：

  3-氨基-5-溴-2-甲氧基吡啶 在 4-二甲氨基吡啶 、 tris-(dibenzylideneacetone)dipalladium(0) 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium t-butanolate 作用下， 以 吡啶 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 生成 N‐(5‐((diphenylmethylene)amino)‐2‐methoxypyridin‐3‐yl)methanesulfonamide
  参考文献：
  名称：

  Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold

  摘要：

  Phosphoinositide 3-kinase (PI3K) is an important target in oncology due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors. A series of 4-amino-6-methyl-1,3,5-triazine sulfonamides were synthesized and evaluated as inhibitors of PI3K. The synthesis, in vitro biological activities, pharmacokinetic and in vivo pharmacodynamic profiling of these compounds are described. The most promising compound from this investigation (compound 3j) was found to be a pan class I PI3K inhibitor with a moderate (>10-fold) selectivity over the mammalian target of rapamycin (mTOR) in the enzyme assay. In a U87 MG cellular assay measuring phosphorylation of Akt, compound 3j displayed low double digit nanomolar IC50 and exhibited good oral bioavailability in rats (F-oral = 63%). Compound 3j also showed a dose dependent reduction in the phosphorylation of Akt in a U87 tumor pharmacodynamic model with a plasma EC50 = 193 nM (91 ng/mL). (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.078

文献信息

• [EN] INHIBITORS OF PI3 KINASE AND / OR MTOR<br/>[FR] INHIBITEURS DE LA PI3 KINASE ET/OU DU MTOR
  申请人：AMGEN INC

  公开号：WO2010126895A1

  公开（公告）日：2010-11-04

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

  本发明涉及式I的化合物或其药用可接受盐；使用这些化合物治疗疾病或症状的方法，如癌症；以及含有这些化合物的药物组合物，其中变量如本文所定义。
• INHIBITORS OF PI3 KINASE AND/OR MTOR
  申请人：Andrews Kristin

  公开号：US20100273764A1

  公开（公告）日：2010-10-28

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

  本发明涉及公式I的化合物或其药学上可接受的盐；使用该化合物治疗疾病或病症的方法，如癌症；以及含有该化合物的制药组合物，其中变量在此定义。
• Inhibitors of PI3 kinase and/or mTOR
  申请人：D'Angelo Noel

  公开号：US08362241B2

  公开（公告）日：2013-01-29

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

  本发明涉及式I化合物或其药学上可接受的盐；使用该化合物治疗疾病或病症的方法，例如癌症；以及含有该化合物的药物组合物，其中变量如本文所定义。
• Inhibitors of PI3 Kinase and/or mTOR
  申请人：Amgen Inc.

  公开号：US20130079303A1

  公开（公告）日：2013-03-28

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

  本发明涉及公式I的化合物，或其药学可接受的盐；使用这些化合物治疗疾病或病况的方法，如癌症；以及含有这些化合物的药物组合物，其中变量的定义如本文所述。
• Design, synthesis, and evaluation of thiazolecarboxamide derivatives as stimulator of interferon gene inhibitors
  作者：Zechen Jin、Yan Zhang、Xin Luo、Meiyu Geng、Wenhu Duan、Zuoquan Xie、Hefeng Zhang

  DOI：10.1007/s11030-024-10860-6

  日期：2025.2

  Stimulator of interferon gene (STING) plays critical roles in the cytoplasmic DNA-sensing pathway and in the induction of inflammatory response. Aberrant cytoplasmic DNA accumulation and STING activation are implicated in numerous inflammatory and autoimmune diseases. Here, we reported the discovery of a series of thiazolecarboxamide-based STING inhibitors through a molecular planarity/symmetry disruption

  干扰素基因刺激物 (STING) 在细胞质 DNA 传感途径和炎症反应的诱导中发挥着关键作用。异常的细胞质 DNA 积累和 STING 激活与许多炎症和自身免疫性疾病有关。在这里，我们报告了通过分子平面性/对称性破坏策略发现了一系列基于噻唑甲酰胺的 STING 抑制剂。特权化合物15b显着抑制人类和小鼠细胞中的 STING 信号传导并抑制免疫炎症细胞因子水平。体内实验表明， 15b可有效改善 MSA-2 刺激的小鼠和Trex1 -D18N 小鼠中的免疫炎症细胞因子上调。此外，化合物15b在抑制干扰素刺激基因 15 (ISG15) 方面表现出增强的功效，干扰素刺激基因 15 是 STING 的关键正反馈调节因子。总体而言，化合物15b值得进一步开发用于治疗 STING 相关炎症和自身免疫性疾病。  图形概要